[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"biomarker:keratin-31-type-i":3},{"name":4,"total":5,"recruiting":5,"trials":6},"KERATIN 31, TYPE I",3,[7,15,22],{"nct_id":8,"title":9,"phases":10,"status":12,"updated_at":13,"content_modified":14},"NCT05473910","A Phase 1\u002F3 Study of T-Cell Receptor Engineered Donor T Cells in Subjects Undergoing Allogeneic Peripheral Blood Stem Cell Transplantation (ALLOHA-2)",[11],"Phase 1","RECRUITING","2026-08-26T02:16:50.548894Z","2026-07-19T19:36:05.117931Z",{"nct_id":16,"title":17,"phases":18,"status":12,"updated_at":20,"content_modified":21},"NCT06704152","BSB-1001 in Patients Undergoing HLA-Matched Allogenic Hematopoietic Stem Cell Transplant for AML, ALL or MDS",[19],"Phase 1\u002FPhase 2","2026-08-26T02:18:18.766496Z","2026-05-05T02:43:29.733634Z",{"nct_id":23,"title":24,"phases":25,"status":12,"updated_at":26,"content_modified":27},"NCT03326921","HA-1 T TCR T Cell Immunotherapy for the Treatment of Patients With Relapsed or Refractory Acute Leukemia After Donor Stem Cell Transplant",[11],"2026-08-26T02:19:00.742020Z","2026-05-05T02:43:27.769481Z"]